TRIALS OF SINGLE-AGENT AND COMBINATION CHEMOTHERAPY FOR ADVANCED CANCER OF THE PANCREAS

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (1-2) , 65-68
Abstract
In 127 patients with advanced measurable pancreatic cancer, objective response rates of 2% (melphalan), 10% (5-FU [5-fluorouracil] and methyl-CCNU [1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea]) and 7% (5-FU, methyl-CCNU and streptozocin) were achieved. No responses occurred in the 28 patients treated with VP-16-213 [vepeside] who had already received prior chemotherapy. Toxicity was greater for the 2- and 3-drug combinations than for melphalan. There was no difference in survival following use of the 3 treatment regimens. Further studies are needed to develop effective chemotherapy for patients with cancer of the pancreas.

This publication has 0 references indexed in Scilit: